Navigation Links
aTyr Pharma to Present at BioPharm America 2009
Date:9/14/2009

SAN DIEGO, Sept. 14 /PRNewswire/ -- aTyr Pharma, Inc., a biopharmaceutical company discovering and developing a new class of naturally occurring proteins as biotherapeutics, will present at the BioPharm America 2009 conference in San Francisco, CA on Friday, September 18th. Jeff Watkins, CEO of aTyr Pharma, will present an overview of aTyr Pharma's technology, product engine, and lead program based on naturally occurring resected proteins of the tRNA synthetases. The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including inflammatory, autoimmune, hematopoietic and metabolic disorders.

According to Cheryl Quinn, Director of Business Development at aTyr Pharma, "Because our product engine is based on the emerging new science of resectin proteins, we look forward to introducing aTyr Pharma's exciting new science and portfolio to the attendees of BioPharma America."

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat he
'/>"/>

SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV
2. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
3. Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.
4. NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009
5. ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
6. StoredIQ Shares Expertise at IQPCs eDiscovery Pharma, Biotech and Medical Device Conference
7. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
8. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
9. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
10. Rib-X Pharmaceuticals to Present at the 49th ICAAC
11. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Lyme Research Alliance (LRA), ... research at universities, today announced the awarding of seven ... treatment and cure for Lyme and other tick-borne diseases. ... applications in its history—over 20 grant proposals—a 100 percent ... pleased to receive so many solid applications from talented ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an ... of a session that he will lead on “Stem Cells” ... February 17-18, 2015 in London. In the interview posted ... Sherley to respond to several questions on the current state ... stem cell toxicity, and future trends in the use of ...
(Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
(Date:9/29/2014)... of diagnostics today, with imaging techniques like MRI ... NMR (nuclear magnetic resonance) increasing steeply over the ... resolution and quality still limit these techniques because ... is hyperpolarization, which involves injecting the patient with ... the distribution and fate of specific molecules in ...
Breaking Biology Technology:Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3
... Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical ... has voluntarily filed a Form 15 with the Securities ... common stock under the Securities and Exchange Act of ... to file periodic and other reports under the Exchange ...
... vaccine is available now for testing worldwide, from Replikins ... the same Replikins peptide technology which provided the surprise ... outbreak/pandemic was on its way ( http://www.replikins.com ... vaccine is its rapid availability; the WHO, CDC and ...
... - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture ... announced that it has reached an agreement with AVAC ... of its Apo AIMilano candidate. AVAC is a private, ... stage commercial businesses that expand Alberta,s value-added industry. , ...
Cached Biology Technology:Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide 2SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC 2SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC 3
(Date:9/30/2014)... at the University of California, San Diego, have completed ... using a method that uses the pixels in an ... known as mesh-free simulation. , The researchers, led by ... at the Jacobs School of Engineering at UC San ... method at the CompIMAGE,14 conference in Pittsburgh this month. ...
(Date:9/30/2014)... all have in common? Unlike most eukaryotic multicellular ... diploid, these organisms are all polyploid, meaning they have ... have 3 and 4 sets of chromosomes, respectively, and ... in fact most plant species are polyploid. Polyploidy, or ... but only recently, with the development of molecular tools, ...
(Date:9/30/2014)... LA JOLLAJoseph Ecker, a Salk professor and Howard ... staff scientist, have been named recipients in the ... of Health (NIH) through the BRAIN (Brain Research ... in neuroscience. The grant, announced September 30, provides ... Salk scientists over three years. , The BRAIN ...
Breaking Biology News(10 mins):First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Salk scientists receive $3 million for BRAIN Initiative grant 2
... February 24, 2012; Wiley-Blackwell, the scientific, technical, medical ... Inc., has launched two new interdisciplinary review publications: ... and Signaling . WIREs Developmental Biology ... produce a complex, fully patterned adult organism. Edited by ...
... different molecules in cancer is an effective way to ... the University of California, San Francisco (UCSF) have foundwork ... include drugs like Avastin. The two-target approach, ... as neuroendocrine pancreatic tumors, may have broad application for ...
... new study by the University of California, Berkeley, Wildlife ... for establishing marine protected areas in Madagascar that offers ... no-take zones to areas that would allow fishing. , ... climate, along with dependence on fisheries and marine resources, ...
Cached Biology News:Wiley-Blackwell launches 2 interdisciplinary review titles in developmental and membrane biology 2Cancer therapy more potent when it hits 2 targets 2Cancer therapy more potent when it hits 2 targets 3Study IDs new marine protected areas in Madagascar 2
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
Biology Products: